• Renuka Shanmugalingam, Helen L Barrett, Amanda Beech, Lucy Bowyer, Tim Crozier, Amanda Davidson, Marloes Dekker Nitert, Kerrie Doyle, Luke Grzeskowiak, Nicole Hall, Hicham Ibrahim Cheikh Hassan, Annemarie Hennessy, Amanda Henry, David Langsford, Vincent Ws Lee, Zachary Munn, Michael J Peek, Joanne M Said, Helen Tanner, Rachel Taylor, Meredith Ward, Jason Waugh, Linda Ly Yen, Ellie Medcalf, Katy Jl Bell, Deonna Ackermann, Robin Turner, and Angela Makris.
• Liverpool Hospital, Sydney, NSW.
• Med. J. Aust. 2024 Jun 17; 220 (11): 582591582-591.

IntroductionHypertensive disorders of pregnancy (HDP) affect up to 10% of all pregnancies annually and are associated with an increased risk of maternal and fetal morbidity and mortality. This guideline represents an update of the Society of Obstetric Medicine of Australia and New Zealand (SOMANZ) guidelines for the management of hypertensive disorders of pregnancy 2014 and has been approved by the National Health and Medical Research Council (NHMRC) under section 14A of the National Health and Medical Research Council Act 1992. In approving the guideline recommendations, NHMRC considers that the guideline meets NHMRC's standard for clinical practice guidelines.Main RecommendationsA total of 39 recommendations on screening, preventing, diagnosing and managing HDP, especially preeclampsia, are presented in this guideline. Recommendations are presented as either evidence-based recommendations or practice points. Evidence-based recommendations are presented with the strength of recommendation and quality of evidence. Practice points were generated where there was inadequate evidence to develop specific recommendations and are based on the expertise of the working group.Changes In Management Resulting From The GuidelineThis version of the SOMANZ guideline was developed in an academically robust and rigorous manner and includes recommendations on the use of combined first trimester screening to identify women at risk of developing preeclampsia, 14 pharmacological and two non-pharmacological preventive interventions, clinical use of angiogenic biomarkers and the long term care of women who experience HDP. The guideline also includes six multilingual patient infographics which can be accessed through the main website of the guideline. All measures were taken to ensure that this guideline is applicable and relevant to clinicians and multicultural women in regional and metropolitan settings in Australia and New Zealand.© 2024 The Authors. Medical Journal of Australia published by John Wiley & Sons Australia, Ltd on behalf of AMPCo Pty Ltd.

24 keywords...

hide…